THEM4 and breast carcinoma: (47) found in their experiments that THEM 4 (CTMP) was highly expressed in the trastuzumab unresponsive group and was positively correlated with Akt activity, indicating that CTMP promotes Akt activation leading to resistance to trastuzumab in HER 2-positive breast cancer patients.